{"success":true,"data":{"pressRelease":{"id":"96076","rtpr_id":"nGNX7nfl5P","ticker":"NKTX","exchange":"NASDAQ","all_tickers":["NKTX"],"title":"Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development","author":"Globe Newswire","published_at":"2026-07-23T05:30:00.106Z","article_body":"Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) --\n* Alyssa Levin appointed to Board of Directors and as Chair of the Audit\nCommittee\n* Clara Cambon-Thiebaud joins as VP, Regulatory Affairs\n* Céline Breda joins as VP, Chemistry, Manufacturing and Controls (CMC)\nParis, France and New York, USA, July 23, 2026 – Cyllene Therapeutics\n(“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1)\nvector technology in neurology, today announced the appointment of Alyssa\nLevin to its Board of Directors, where she will also serve as Chair of the\nAudit Committee. The company has also strengthened its leadership team with\ntwo key additions. Clara Cambon-Thiebaud joins as Vice President, Regulatory\nAffairs, based in New York, and Céline Breda as Vice President, Chemistry\nManufacturing and Controls (CMC). This leadership team expansion comes as\nCyllene Tx advances its lead candidate, EG110A, towards late-stage clinical\ndevelopment for neurogenic bladder-related incontinence.\n\n\"Building a world-class leadership team is essential as we advance Cyllene Tx\ninto its next phase of growth,” said Philippe Cambon, MD, PhD, Co-Founder\nand Chief Executive Officer of Cyllene Tx. “These appointments strengthen\nour existing team by adding the late-stage expertise and experience necessary\nto meet our upcoming corporate goals. Alyssa brings exceptional financial\nleadership and public company expertise, including significant experience in\ncapital markets, strategic transactions, and corporate governance. Clara is a\nhighly accomplished regulatory leader with deep global expertise in advancing\ninnovative therapies from early development through approval. Céline has\ndedicated her career to the manufacturing of biologics both in biopharma\ncompanies and contract development and manufacturing organizations (CDMOs).\nTogether, they give us the depth needed to execute on our strategy and move\nour pipeline forward.\"\n\nMs. Levin is a seasoned biotechnology finance executive with more than 15\nyears of experience leading financial strategy, capital markets, mergers and\nacquisitions, and operational growth across both public and private life\nsciences companies. She has raised more than $500 million through financings,\nled transformative corporate transactions, and built high-performing finance\norganizations while developing strong relationships across the investor,\nbanking, and biopharmaceutical communities.\n\nShe currently serves as Chief Financial Officer of Radionetics Oncology, a\nclinical-stage radiopharmaceutical company operating under a strategic\nagreement with Eli Lilly, where she leads finance, legal, and people\noperations. She previously served as Chief Financial and Business Officer at\nNkarta (Nasdaq: NKTX), where she was instrumental in a $240 million follow-on\npublic offering, Chief Financial Officer of ViaCyte, co-leading the company's\n$320 million acquisition by Vertex Pharmaceuticals, and held CFO positions at\nTentarix Biotherapeutics and Bird Rock Bio. Ms. Levin began her career in\naudit and capital markets advisory at PwC LLP and The Siegfried Group and is a\nChartered Professional Accountant (Canada).\n\n\"I am honored to join the Cyllene Tx Board as the company builds toward its\nnext phase of growth. With EG110A advancing and the clinical pipeline\nexpanding, I look forward to working with the Board and management team to\nhelp bolster the financial and governance infrastructure a company at this\nstage needs,” said Ms. Levin.\n\nMs. Cambon-Thiebaud joins Cyllene Tx as Vice President, Regulatory Affairs,\nbringing more than 15 years of global regulatory leadership spanning multiple\ntherapeutic modalities and all phases of drug development. Throughout her\ncareer, she has contributed to more than 30 development programs from\npreclinical research through successful regulatory filings and product\napprovals. A French-trained pharmacist based in the United States, Ms.\nCambon-Thiebaud began her career at Genentech before establishing a successful\nregulatory consulting practice focused on supporting innovative biotechnology\ncompanies. She has advised clients on global regulatory strategy, filing\nreadiness, regulatory organization development, and Health Authority\ninteractions, helping companies design differentiated development strategies\nand successfully navigate complex regulatory pathways to bring important new\ntherapies to patients.\n\n\"I am delighted to join Cyllene Tx at such an exciting time and especially\nlook forward to working with Regulators globally on the strategy to advance\nour lead program EG110A and, more broadly, our HERMES platform to address\nimportant medical needs,\" said Ms. Cambon-Thiebaud.\n\nMs. Breda joins Cyllene as Vice President, Chemistry, Manufacturing and\nControls (CMC). She is a seasoned biopharmaceutical executive with more than\n25 years of experience leading CMC strategy, pharmaceutical development and\nmanufacturing operations for innovative biologics. Throughout her career, she\nhas played a key role in advancing vaccines, viral vectors and other complex\nbiological products from development into clinical manufacturing. Recognized\nfor her scientific rigor and operational leadership, she brings extensive\nexpertise in process development, technology transfer, GMP manufacturing,\nexternal network management and global CMC strategy.\n\n\"EG110A represents a real opportunity to improve patients' lives, and I'm\nlooking forward to building the CMC strategy that will carry it through the\nnext phase of clinical manufacturing and beyond. Cyllene Tx is building a very\ntalented team, and I’m glad to be joining at this important stage,” said\nMs. Breda.\n\nAbout Cyllene Therapeutics\n\nCyllene Therapeutics is the global leader in non-replicating HSV-1 (nrHSV-1)\nvector technology in neurology. Cyllene Tx is currently executing a Phase 1/2\nstudy in the US with its lead DNA medicine candidate, EG110A, in patients with\nneurogenic detrusor overactivity (neurogenic bladder)-related incontinence.\nThis is the first human study with nrHSV vectors targeting sensory\nneuron-based diseases. EG110A is being developed to address multiple severe\nbladder diseases, including overactive bladder (OAB), and has the potential to\nbe a major improvement over existing therapies, resulting in better care for\npatients and lower costs for healthcare systems. The company’s unique HERMES\nplatform delivers pinpoint neurotherapeutics to treat prevalent diseases of\nthe peripheral and central nervous system. Its vectors can achieve focal\ntransduction and then selective expression of transgenes in targeted subsets\nof neurons. With demonstrated clinical safety and possible repeat dosing, the\nlarge payload capacity of nrHSV-1 vectors allows for versatile DNA delivery\nand smarter DNA medicine.\n\nFor more information      www.cyllene-tx.com       \nwww.linkedin.com/company/cyllene-tx\n\nContacts\nCompany: Cyllene Therapeutics                               \n                                   \nPhilippe Chambon, M.D., Ph.D.,\nFounder, Chaiman and CEO \npchambon@cyllene-tx.com\n\nMedia Relations: Rose Piquante Consulting\nSophie Baumont\nsophie.baumont@rosepiquante-consulting.com \n+33 627 74 7449\n\n \n\n\n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d575ca4b-3ffd-4ec0-9934-cc94d4e97fa4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7nfl5P","title":"Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development","author":"Globe Newswire","ticker":"NKTX","created":"2026-07-23T05:30:00.106Z","tickers":["NKTX"],"exchange":"NASDAQ","article_body":"Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) --\n* Alyssa Levin appointed to Board of Directors and as Chair of the Audit\nCommittee\n* Clara Cambon-Thiebaud joins as VP, Regulatory Affairs\n* Céline Breda joins as VP, Chemistry, Manufacturing and Controls (CMC)\nParis, France and New York, USA, July 23, 2026 – Cyllene Therapeutics\n(“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1)\nvector technology in neurology, today announced the appointment of Alyssa\nLevin to its Board of Directors, where she will also serve as Chair of the\nAudit Committee. The company has also strengthened its leadership team with\ntwo key additions. Clara Cambon-Thiebaud joins as Vice President, Regulatory\nAffairs, based in New York, and Céline Breda as Vice President, Chemistry\nManufacturing and Controls (CMC). This leadership team expansion comes as\nCyllene Tx advances its lead candidate, EG110A, towards late-stage clinical\ndevelopment for neurogenic bladder-related incontinence.\n\n\"Building a world-class leadership team is essential as we advance Cyllene Tx\ninto its next phase of growth,” said Philippe Cambon, MD, PhD, Co-Founder\nand Chief Executive Officer of Cyllene Tx. “These appointments strengthen\nour existing team by adding the late-stage expertise and experience necessary\nto meet our upcoming corporate goals. Alyssa brings exceptional financial\nleadership and public company expertise, including significant experience in\ncapital markets, strategic transactions, and corporate governance. Clara is a\nhighly accomplished regulatory leader with deep global expertise in advancing\ninnovative therapies from early development through approval. Céline has\ndedicated her career to the manufacturing of biologics both in biopharma\ncompanies and contract development and manufacturing organizations (CDMOs).\nTogether, they give us the depth needed to execute on our strategy and move\nour pipeline forward.\"\n\nMs. Levin is a seasoned biotechnology finance executive with more than 15\nyears of experience leading financial strategy, capital markets, mergers and\nacquisitions, and operational growth across both public and private life\nsciences companies. She has raised more than $500 million through financings,\nled transformative corporate transactions, and built high-performing finance\norganizations while developing strong relationships across the investor,\nbanking, and biopharmaceutical communities.\n\nShe currently serves as Chief Financial Officer of Radionetics Oncology, a\nclinical-stage radiopharmaceutical company operating under a strategic\nagreement with Eli Lilly, where she leads finance, legal, and people\noperations. She previously served as Chief Financial and Business Officer at\nNkarta (Nasdaq: NKTX), where she was instrumental in a $240 million follow-on\npublic offering, Chief Financial Officer of ViaCyte, co-leading the company's\n$320 million acquisition by Vertex Pharmaceuticals, and held CFO positions at\nTentarix Biotherapeutics and Bird Rock Bio. Ms. Levin began her career in\naudit and capital markets advisory at PwC LLP and The Siegfried Group and is a\nChartered Professional Accountant (Canada).\n\n\"I am honored to join the Cyllene Tx Board as the company builds toward its\nnext phase of growth. With EG110A advancing and the clinical pipeline\nexpanding, I look forward to working with the Board and management team to\nhelp bolster the financial and governance infrastructure a company at this\nstage needs,” said Ms. Levin.\n\nMs. Cambon-Thiebaud joins Cyllene Tx as Vice President, Regulatory Affairs,\nbringing more than 15 years of global regulatory leadership spanning multiple\ntherapeutic modalities and all phases of drug development. Throughout her\ncareer, she has contributed to more than 30 development programs from\npreclinical research through successful regulatory filings and product\napprovals. A French-trained pharmacist based in the United States, Ms.\nCambon-Thiebaud began her career at Genentech before establishing a successful\nregulatory consulting practice focused on supporting innovative biotechnology\ncompanies. She has advised clients on global regulatory strategy, filing\nreadiness, regulatory organization development, and Health Authority\ninteractions, helping companies design differentiated development strategies\nand successfully navigate complex regulatory pathways to bring important new\ntherapies to patients.\n\n\"I am delighted to join Cyllene Tx at such an exciting time and especially\nlook forward to working with Regulators globally on the strategy to advance\nour lead program EG110A and, more broadly, our HERMES platform to address\nimportant medical needs,\" said Ms. Cambon-Thiebaud.\n\nMs. Breda joins Cyllene as Vice President, Chemistry, Manufacturing and\nControls (CMC). She is a seasoned biopharmaceutical executive with more than\n25 years of experience leading CMC strategy, pharmaceutical development and\nmanufacturing operations for innovative biologics. Throughout her career, she\nhas played a key role in advancing vaccines, viral vectors and other complex\nbiological products from development into clinical manufacturing. Recognized\nfor her scientific rigor and operational leadership, she brings extensive\nexpertise in process development, technology transfer, GMP manufacturing,\nexternal network management and global CMC strategy.\n\n\"EG110A represents a real opportunity to improve patients' lives, and I'm\nlooking forward to building the CMC strategy that will carry it through the\nnext phase of clinical manufacturing and beyond. Cyllene Tx is building a very\ntalented team, and I’m glad to be joining at this important stage,” said\nMs. Breda.\n\nAbout Cyllene Therapeutics\n\nCyllene Therapeutics is the global leader in non-replicating HSV-1 (nrHSV-1)\nvector technology in neurology. Cyllene Tx is currently executing a Phase 1/2\nstudy in the US with its lead DNA medicine candidate, EG110A, in patients with\nneurogenic detrusor overactivity (neurogenic bladder)-related incontinence.\nThis is the first human study with nrHSV vectors targeting sensory\nneuron-based diseases. EG110A is being developed to address multiple severe\nbladder diseases, including overactive bladder (OAB), and has the potential to\nbe a major improvement over existing therapies, resulting in better care for\npatients and lower costs for healthcare systems. The company’s unique HERMES\nplatform delivers pinpoint neurotherapeutics to treat prevalent diseases of\nthe peripheral and central nervous system. Its vectors can achieve focal\ntransduction and then selective expression of transgenes in targeted subsets\nof neurons. With demonstrated clinical safety and possible repeat dosing, the\nlarge payload capacity of nrHSV-1 vectors allows for versatile DNA delivery\nand smarter DNA medicine.\n\nFor more information      www.cyllene-tx.com       \nwww.linkedin.com/company/cyllene-tx\n\nContacts\nCompany: Cyllene Therapeutics                               \n                                   \nPhilippe Chambon, M.D., Ph.D.,\nFounder, Chaiman and CEO \npchambon@cyllene-tx.com\n\nMedia Relations: Rose Piquante Consulting\nSophie Baumont\nsophie.baumont@rosepiquante-consulting.com \n+33 627 74 7449\n\n \n\n\n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d575ca4b-3ffd-4ec0-9934-cc94d4e97fa4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-23T05:30:00.185526752Z","server_sent_at_ms":1784784600185},"received_at":"2026-07-23T05:30:00.238Z","source_url":"https://www.globenewswire.com/news-release/2026/07/23/3331872/0/en/Cyllene-Therapeutics-Expands-Leadership-Team-to-Support-Corporate-Growth-and-Clinical-Product-Development.html"},"analysis":{"id":"85127","press_release_id":"96076","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Alyssa Levin, formerly the CFO of Nkarta (NKTX), has joined Cyllene Therapeutics' Board of Directors as Chair of the Audit Committee.\n\nThe release details Cyllene's strategic hires in regulatory affairs and CMC to support its lead candidate EG110A, a DNA medicine for neurogenic bladder currently in a Phase 1/2 study.\n\nThese personnel changes affect Cyllene Therapeutics and have no direct operational or financial impact on Nkarta.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Irrelevant to NKTX; news concerns former executive's appointment at Cyllene Therapeutics."},"keyFigures":null,"quotedText":"Building a world-class leadership team is essential as we advance Cyllene Tx into its next phase of growth","namedEntities":{"people":[{"name":"Alyssa Levin","role":"Board of Directors / Chair of Audit Committee"},{"name":"Clara Cambon-Thiebaud","role":"VP, Regulatory Affairs"},{"name":"Céline Breda","role":"VP, Chemistry, Manufacturing and Controls (CMC)"},{"name":"Philippe Cambon","role":"Co-Founder and Chief Executive Officer of Cyllene Tx"},{"name":"Sophie Baumont","role":"Media Relations"}],"products":["EG110A","HERMES platform"],"companies":[{"name":"Cyllene Therapeutics","relationship":"subject of press release"},{"name":"Nkarta","ticker":"NKTX","relationship":"former employer"},{"name":"Radionetics Oncology","relationship":"current employer"},{"name":"Eli Lilly","relationship":"strategic partner"},{"name":"ViaCyte","relationship":"former employer"},{"name":"Vertex Pharmaceuticals","relationship":"acquirer"},{"name":"Tentarix Biotherapeutics","relationship":"former employer"},{"name":"Bird Rock Bio","relationship":"former employer"},{"name":"Genentech","relationship":"former employer"},{"name":"PwC LLP","relationship":"former employer"},{"name":"The Siegfried Group","relationship":"former employer"}],"dollarAmounts":[{"amount":"$500 million","context":"raised by Alyssa Levin through financings"},{"amount":"$240 million","context":"follow-on public offering at Nkarta led by Alyssa Levin"},{"amount":"$320 million","context":"acquisition of ViaCyte by Vertex Pharmaceuticals"}]},"materialImpact":{"score":1,"reasoning":"The press release details leadership appointments at Cyllene Therapeutics. While it mentions Alyssa Levin's past role as CFO of Nkarta (NKTX), the event is operationally irrelevant to the input ticker."},"tickerRelevance":{"others":[],"primary":"NKTX"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"personnel-change-at-other-company","issuerAuthored":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Alyssa Levin, formerly the CFO of Nkarta (NKTX), has joined Cyllene Therapeutics' Board of Directors as Chair of the Audit Committee.\n\nThe release details Cyllene's strategic hires in regulatory affairs and CMC to support its lead candidate EG110A, a DNA medicine for neurogenic bladder currently in a Phase 1/2 study.\n\nThese personnel changes affect Cyllene Therapeutics and have no direct operational or financial impact on Nkarta.","key_figures":null,"named_entities":{"people":[{"name":"Alyssa Levin","role":"Board of Directors / Chair of Audit Committee"},{"name":"Clara Cambon-Thiebaud","role":"VP, Regulatory Affairs"},{"name":"Céline Breda","role":"VP, Chemistry, Manufacturing and Controls (CMC)"},{"name":"Philippe Cambon","role":"Co-Founder and Chief Executive Officer of Cyllene Tx"},{"name":"Sophie Baumont","role":"Media Relations"}],"products":["EG110A","HERMES platform"],"companies":[{"name":"Cyllene Therapeutics","relationship":"subject of press release"},{"name":"Nkarta","ticker":"NKTX","relationship":"former employer"},{"name":"Radionetics Oncology","relationship":"current employer"},{"name":"Eli Lilly","relationship":"strategic partner"},{"name":"ViaCyte","relationship":"former employer"},{"name":"Vertex Pharmaceuticals","relationship":"acquirer"},{"name":"Tentarix Biotherapeutics","relationship":"former employer"},{"name":"Bird Rock Bio","relationship":"former employer"},{"name":"Genentech","relationship":"former employer"},{"name":"PwC LLP","relationship":"former employer"},{"name":"The Siegfried Group","relationship":"former employer"}],"dollarAmounts":[{"amount":"$500 million","context":"raised by Alyssa Levin through financings"},{"amount":"$240 million","context":"follow-on public offering at Nkarta led by Alyssa Levin"},{"amount":"$320 million","context":"acquisition of ViaCyte by Vertex Pharmaceuticals"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-23T05:38:53.984Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"personnel-change-at-other-company","issuerAuthored":false}},"durationMs":187276,"modelName":"glm-4.7"}}